Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYG0W5
|
|||
| Drug Name |
Coversin
|
|||
| Drug Type |
Recombinant?protein
|
|||
| Indication | Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0; ICD-10: D59.5] | Phase 3 | [1] | |
| Company |
Akari Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C5 (CO5) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Prion diseases | ||||
| Pertussis | ||||
| Staphylococcus aureus infection | ||||
| Herpes simplex infection | ||||
| Systemic lupus erythematosus | ||||
| Reactome | Activation of C3 and C5 | |||
| Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | ||||
| Regulation of Complement cascade | ||||
| WikiPathways | Complement Activation, Classical Pathway | |||
| Human Complement System | ||||
| Spinal Cord Injury | ||||
| Allograft Rejection | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03427060) Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms (CONSENTII). U.S. National Institutes of Health. | |||
| REF 2 | Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.